Want to see IN:MKPL full AI Analyst Report?
Top Page
M K Proteins Limited
(MKPL)
Select Model
Select Model
Rating:51Neutral
Price Target:
₹5.00
▼(-27.43% Downside)
Action:Reiterated
Date:06/03/26
The score is primarily held back by weakened financial quality—sharp margin compression and inconsistent cash-flow conversion—despite improved leverage and a strong FY2026 revenue rebound. Technicals also lean weak (below major moving averages with negative MACD), while valuation appears somewhat demanding at ~27.7x earnings given the profitability and cash-flow risks.
Positive Factors
Revenue Rebound
A clear FY2026 revenue rebound signals recovering demand and improved commercial execution. Sustained top-line growth can help absorb fixed costs, restore operating leverage, and provide cash flow runway for maintenance or targeted investments, strengthening resilience over coming quarters.
Negative Factors
Margin Compression
Substantial margin erosion materially reduces the company's buffer against commodity input swings and price competition. Persistently thin gross and net margins limit internal capital for reinvestment, constrain profitability recovery, and make earnings highly sensitive to cost or pricing shocks.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Rebound
A clear FY2026 revenue rebound signals recovering demand and improved commercial execution. Sustained top-line growth can help absorb fixed costs, restore operating leverage, and provide cash flow runway for maintenance or targeted investments, strengthening resilience over coming quarters.
Read all positive factors
M K Proteins Limited (MKPL) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.81B
Dividend YieldN/A
Average Volume (3M)20.59K
Price to Earnings (P/E)26.9
Beta (1Y)0.93
Revenue Growth43.02%
EPS Growth-18.82%
CountryIN
Employees48
SectorGeneral
Sector StrengthN/A
IndustryPackaged Foods
Share Statistics
EPS (TTM)0.24
Shares Outstanding375,372,000
10 Day Avg. Volume17,806
30 Day Avg. Volume20,591
Financial Highlights & Ratios
PEG Ratio-1.18
Price to Book (P/B)1.92
Price to Sales (P/S)0.38
P/FCF Ratio76.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
M K Proteins Limited Business Overview & Revenue Model
Company Description
M. K. Proteins Limited specializes in the production and commercial activities related to a range of refined vegetable oils and their associated derivatives. The company's diverse offerings include refined varieties such as rice bran, sunflower, c...
How the Company Makes Money
MKPL generates revenue by refining and selling edible oils, such as mustard oil, soybean oil, and palm oil. The company sources raw materials, including oilseeds and crude oil, which are then processed at its facilities into finished products. The...
M K Proteins Limited Financial Statement Overview
Summary
Income Statement
55
Neutral
Balance Sheet
72
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.25B | 3.83B | 2.68B | 2.46B | 3.15B | 2.56B |
| Gross Profit | 196.86M | 109.81M | 156.53M | 192.91M | 204.93M | 186.78M |
| EBITDA | 146.78M | 114.17M | 129.08M | 170.99M | 176.52M | 157.88M |
| Net Income | 94.29M | 68.29M | 83.97M | 112.12M | 109.35M | 101.84M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 1.31B | 1.31B | 962.46M | 1.03B | 861.48M |
| Cash, Cash Equivalents and Short-Term Investments | 338.00K | 4.38M | 338.00K | 923.24K | 624.84K | 66.62K |
| Total Debt | 0.00 | 371.38M | 387.24M | 200.83M | 455.35M | 367.84M |
| Total Liabilities | -694.66M | 548.97M | 611.04M | 351.70M | 533.55M | 465.44M |
| Stockholders Equity | 694.66M | 763.00M | 694.66M | 610.76M | 498.64M | 396.04M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 19.10M | -183.51M | 265.13M | -58.80M | -116.95M |
| Operating Cash Flow | 0.00 | 38.05M | -161.28M | 324.16M | -58.73M | -101.22M |
| Investing Cash Flow | 0.00 | -17.18M | -14.82M | -58.78M | 133.85K | -15.28M |
| Financing Cash Flow | 0.00 | -16.83M | 175.52M | -265.08M | 59.15M | 116.56M |
M K Proteins Limited Technical Analysis
Negative
6.89
Price Trends
5.03
Negative
5.05
Negative
5.73
Negative
Market Momentum
-0.07
Positive
44.78
Neutral
24.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MKPL, the sentiment is Negative. The current price of 6.89 is above the 20-day moving average (MA) of 4.86, above the 50-day MA of 5.03, and above the 200-day MA of 5.73, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 44.78 is Neutral, neither overbought nor oversold. The STOCH value of 24.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MKPL.
M K Proteins Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ₹3.94B | 12.35 | ― | 0.43% | 25.49% | -8.35% | |
74 Outperform | ₹61.76B | 16.92 | ― | ― | 23.14% | 50.41% | |
57 Neutral | ₹1.39B | 14.86 | ― | ― | 32.25% | 71.27% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | ₹4.12B | 22.28 | ― | ― | 17.36% | 24.73% | |
51 Neutral | ₹1.81B | 26.90 | ― | ― | 43.02% | -18.82% | |
48 Neutral | ₹7.19B | 13.80 | ― | ― | 44.02% | 12.33% |
* General Sector Average
IN:MKPL
M K Proteins Limited
4.81
-2.62
-35.26%
IN:GOKUL
Gokul Refoils & Solvent Ltd.
41.65
-2.37
-5.38%
IN:GOKULAGRO
Gokul Agro Resources Ltd.
209.30
55.02
35.66%
IN:KRITINUT
Kriti Nutrients Limited
78.61
-29.83
-27.51%
IN:MUKKA
Mukka Proteins Limited
23.98
-6.00
-20.01%
IN:ROML
Raj Oil Mills Limited
46.25
-12.09
-20.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.